

Hugo Vanderstichele

List of Publications by Citations

Source: <https://exaly.com/author-pdf/10949982/hugo-vanderstichele-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89
papers

11,219
citations

45
h-index

91
g-index

91
ext. papers

12,436
ext. citations

5.8
avg. IF

5.32
L-index

#	Paper	IF	Citations
89	Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. <i>Nature</i> , 1998 , 391, 387-90	50.4	1580
88	Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. <i>Annals of Neurology</i> , 2009 , 65, 403-13	9.4	1502
87	Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. <i>Archives of Neurology</i> , 1999 , 56, 673-80		518
86	Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. <i>Archives of Neurology</i> , 2001 , 58, 373-9		372
85	Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. <i>Clinical Chemistry</i> , 2005 , 51, 336-45	5.5	358
84	Tau and Aβ2 in Cerebrospinal Fluid from Healthy Adults 21-83 Years of Age: Establishment of Reference Values. <i>Clinical Chemistry</i> , 2001 , 47, 1776-1781	5.5	351
83	Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. <i>Neuroscience Letters</i> , 2001 , 297, 187-90	3.3	347
82	Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. <i>Archives of Neurology</i> , 2010 , 67, 949-56		344
81	Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. <i>Archives of General Psychiatry</i> , 2004 , 61, 95-102		336
80	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimers and Dementia</i> , 2011 , 7, 386-395.e6	1.2	291
79	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimers and Dementia</i> , 2013 , 9, 251-61	1.2	289
78	Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2000 , 7, 245-58	2.7	268
77	CSF Aβ2/Aβ0 and Aβ2/Aβ8 ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016 , 3, 154-65	5.3	244
76	Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. <i>Acta Neuropathologica</i> , 2011 , 121, 597-609	14.3	220
75	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimers and Dementia</i> , 2012 , 8, 65-73	1.2	210
74	Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. <i>American Journal of Pathology</i> , 2000 , 157, 1283-98	5.8	198
73	Evaluation of plasma Aβeta(40) and Aβeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010 , 31, 357-67	5.6	197

72	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. <i>Neurobiology of Aging</i> , 2008 , 29, 1143-59	5.6	181
71	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimers and Dementia</i> , 2017 , 13, 45-58 ^{1.2}		163
70	Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. <i>Journal of Alzheimers Disease</i> , 2000 , 2, 199-206	4.3	160
69	The discrepancy between presenilin subcellular localization and gamma-secretase processing of amyloid precursor protein. <i>Journal of Cell Biology</i> , 2001 , 154, 731-40	7.3	143
68	Comparison of analytical platforms for cerebrospinal fluid measures of Aβ amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. <i>Archives of Neurology</i> , 2011 , 68, 1137-44		138
67	Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. <i>Clinical Chemistry</i> , 2005 , 51, 189-95	5.5	137
66	Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. <i>Acta Neuropathologica</i> , 2011 , 122, 401-13	14.3	123
65	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015 , 11, 41-55	15	116
64	Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. <i>Acta Neurologica Scandinavica</i> , 2003 , 179, 47-51	3.8	107
63	Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. <i>Journal of Alzheimers Disease</i> , 2007 , 12, 255-60	4.3	105
62	Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006 , 44, 1472-80	5.9	100
61	Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. <i>Journal of Neuroscience</i> , 2000 , 20, 6452-8	6.6	100
60	Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. <i>Archives of Neurology</i> , 2004 , 61, 333-7		94
59	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015 , 138, 2701-15.2		86
58	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. <i>Alzheimers and Dementia</i> , 2014 , 10, 53-61	1.2	84
57	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. <i>Neurobiology of Aging</i> , 2008 , 29, 812-8	5.6	84
56	CSF Aβ an excellent but complicated Alzheimer's biomarker - a route to standardisation. <i>Clinica Chimica Acta</i> , 2017 , 467, 27-33	6.2	82
55	The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001 , 12, 257-64	2.6	81

54	Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. <i>Journal of Alzheimers Disease</i> , 2012 , 31, 13-20	4.3	79
53	Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. <i>Clinical Chemistry</i> , 2005 , 51, 1650-60	5.5	73
52	Differential role of CSF fatty acid binding protein 3, β -synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. <i>Alzheimers Research and Therapy</i> , 2017 , 9, 52	9	69
51	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β 2. <i>Biomarkers in Medicine</i> , 2012 , 6, 409-17	2.3	66
50	Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. <i>Methods</i> , 2012 , 56, 484-93	4.6	64
49	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimers and Dementia</i> , 2018 , 14, 1313-1333	1.2	61
48	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimers and Dementia</i> , 2015 , 11, 772-91	1.2	53
47	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. <i>Neurobiology of Aging</i> , 2010 , 31, 1867-76	5.6	53
46	Assessing the commutability of reference material formats for the harmonization of amyloid- β measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016 , 54, 1177-91	5.9	48
45	Evidence that A β 42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype. <i>Neurobiology of Disease</i> , 1999 , 6, 280-7	7.5	48
44	Improved protocol for measurement of plasma β -amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. <i>Alzheimers and Dementia</i> , 2012 , 8, 250-60	1.2	45
43	Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. <i>Alzheimers and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 871-882	6	45
42	How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A β /A β ratio. <i>Alzheimers and Dementia</i> , 2017 , 13, 885-892	1.2	44
41	Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. <i>Clinical Chemistry</i> , 2012 , 58, 787-9	5.5	44
40	The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease. <i>American Journal of Human Genetics</i> , 1999 , 64, 290-2	11	43
39	Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. <i>Mechanisms of Ageing and Development</i> , 2001 , 122, 2005-11	5.6	39
38	A user's guide for β -synuclein biomarker studies in biological fluids: Perianalytical considerations. <i>Movement Disorders</i> , 2017 , 32, 1117-1130	7	35
37	Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. <i>Journal of Alzheimers Disease</i> , 2013 , 33, 117-31	4.3	34

36	Relevance of A β 2/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM Scale. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 138	5.3	32
35	Ultrasensitive Detection of Plasma Amyloid- β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 71, 775-783	4.3	29
34	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 19-35	4.3	29
33	Plasma Amyloid- β Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 977-987	4.3	26
32	Antibody-based methods for the measurement of β -synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. <i>Journal of Neurochemistry</i> , 2019 , 149, 126-138	6	26
31	Plasma amyloid- β levels, cerebral atrophy and risk of dementia: a population-based study. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 63	9	25
30	Analytical aspects of molecular Alzheimer's disease biomarkers. <i>Biomarkers in Medicine</i> , 2012 , 6, 377-89	2.3	24
29	Commutability of the certified reference materials for the standardization of β -amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β -amyloid 1-40 measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 2058-2066	5.9	23
28	Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. <i>Alzheimer's and Dementia</i> , 2017 , 13, 701-709	1.2	22
27	Validation of a multiplex assay for simultaneous quantification of amyloid- β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics. <i>Journal of Alzheimer's Disease</i> , 2012 , 32, 905-18	4.3	22
26	Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 55-67	4.3	22
25	First amyloid β -42 certified reference material for re-calibrating commercial immunoassays. <i>Alzheimer's and Dementia</i> , 2020 , 16, 1493-1503	1.2	20
24	C-Reactive Protein, Plasma Amyloid- β Levels, and Their Interaction With Magnetic Resonance Imaging Markers. <i>Stroke</i> , 2018 , 49, 2692-2698	6.7	20
23	Validation of ELISA methods for quantification of total tau and phosphorylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies. <i>Journal of Alzheimer's Disease</i> , 2011 , 26, 531-41	4.3	19
22	Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients. <i>European Journal of Paediatric Neurology</i> , 2008 , 12, 334-41	3.8	17
21	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 51, 97-106	4.3	17
20	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 169-183	4.3	16
19	Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. <i>NeuroToxicology</i> , 2004 , 25, 471-80	4.4	16

18	Cerebrospinal Fluid Total and Phosphorylated β Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy. <i>Molecular Neurobiology</i> , 2019 , 56, 3476-3483	6.2	15
17	Validation of assays for measurement of amyloid- β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab. <i>Journal of Alzheimers Disease</i> , 2013 , 34, 897-910	4.3	15
16	Plasma A β (Amyloid- β) Levels and Severity and Progression of Small Vessel Disease. <i>Stroke</i> , 2018 , 49, 884-890	6.7	14
15	No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. <i>Molecular Neurodegeneration</i> , 2016 , 11, 65	1.9	13
14	Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, β Synuclein, and total tau in combination with A β (1-42)/A β (1-40). <i>Alzheimers Research and Therapy</i> , 2017 , 9, 40	9	12
13	Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003 , 16, 93-7	2.6	12
12	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. <i>Alzheimers and Dementia</i> , 2021 , 17, 1575-1582	1.2	12
11	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. <i>Alzheimers Research and Therapy</i> , 2016 , 8, 42	9	10
10	Potential sources of interference on Abeta immunoassays in biological samples. <i>Alzheimers Research and Therapy</i> , 2012 , 4, 39	9	10
9	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 2518-2530	5.3	10
8	Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults. <i>Journal of Neurochemistry</i> , 2019 , 149, 139-157	6	8
7	Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid. <i>Clinical Chemistry</i> , 2005 , 51, 1057-60	5.5	8
6	Accelerating drug development for Alzheimer's disease through the use of data standards. <i>Alzheimers and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 273-283	6	7
5	A First Tetraplex Assay for the Simultaneous Quantification of Total β Synuclein, Tau, β Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. <i>PLoS ONE</i> , 2016 , 11, e0153564	3.7	6
4	Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays. <i>SLAS Technology</i> , 2018 , 23, 188-197	3	3
3	Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach. <i>Alzheimers Research and Therapy</i> , 2014 , 6, 23	9	3
2	O4-11-06: The confidence level of established cut-off values for CSF Alzheimer's disease-specific biomarkers 2015 , 11, P298-P298		2
1	Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for β Synuclein measurement. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 1653-1661	5.9	1

